Sichuan Biokin Stock Hits Day High with 8.8% Surge Amid Strong Performance

Sichuan Biokin Pharmaceutical Co., Ltd. has experienced significant activity today, with the stock rising by 8.8% as of July 1, 2026. The stock reached an intraday high of CNY 323.00, reflecting a strong performance compared to the China Shanghai Composite, which only gained 0.44% on the same day. Over the past week, Sichuan Biokin has shown remarkable growth of 29.14%, and its one-month performance stands at an impressive 50.08%. However, the company has faced challenges, with net sales for the first nine months declining by 63.52%, resulting in a net profit loss of CNY 500.37 million. The operating cash flow has also been notably low at CNY -2,331.46 million. Despite these financial hurdles, the stock has demonstrated a substantial three-year performance increase of 342.1%, significantly outpacing the China Shanghai Composite's 28.43% growth during the same period. As a large-cap player in the Pharmaceuticals & Biotechnology sector, Sichuan Biokin continues to navigate a complex market landscape.